TNF and rheumatoid arthritis: This trial compared patients treated with tofacitinib versus two TNF inhibitors (adalimumab and etanercept) in a large population of 4362 RA patients over 50 years of age with at least one cardiovascular risk factor, such as current cigarette smoker, high blood pressure, or high-density lipoprotein (HDL).